Abstract
Purpose
An increasing number of studies have shown that insulinoma-associated protein 1 (INSM1) is a robust marker for the diagnosis of gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN). The overall diagnostic accuracy of INSM1 for GEP-NEN remains unclear. The purpose of this study is to estimate the diagnostic value of INSM1 for GEP-NEN through a meta-analysis.
Methods
We searched relevant studies addressing the accuracy of INSM1 in the diagnosis of GEP-NEN from PubMed, Web of Science, Embase, Cochrane Library and China National Knowledge Infrastructure (CNKI) as well as from reference lists since the establishment of the database to January 12, 2021. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and summary receiver operating characteristic (SROC) curves were used to comprehensively evaluate the diagnostic value of INSM1 for GEP-NEN. Statistical analysis was performed by Stata 15.0 and RevMan 5.4.
Results
Nine studies with a total of 393 patients were included in the meta-analysis. The meta-analysis results showed that the pooled sensitivity and specificity of INSM1 for the diagnosis of GEP-NEN were 0.99 (95% CI: 0.87–1.00) and 0.96 (95% CI: 0.93–0.98), respectively. The PLR and NLR were 23.3 (95% CI: 13.3–40.8) and 0.01 (95% CI: 0.00–0.14), respectively. The DOR was 380.31 (95% CI: 164.14–881.21), and the area under the curve (AUC) of SROC curve was 0.98 (95% CI: 0.96–0.99).
Conclusions
The results show that INSM1 is an effective marker for the diagnosis of GEP-NEN with high sensitivity and specificity. INSM1 is recommended for clinical application to improve the diagnostic accuracy of GEP-NEN. However, more high-quality studies are needed to confirm these findings.
Similar content being viewed by others
Data availability
All data generated or analyzed during this study are included in this published article.
Code availability
Stata 15.0 and RevMan 5.4 were used for analyzing data. All codes used to generate the results of meta-analysis can be obtained from the authors upon request.
References
D. Putzer, P. Schullian, W. Jaschke, R. Bale, NEN: advancement in diagnosis and minimally invasive therapy. RoFo: Fortschr. auf dem Geb. der Rontgenstrahlen und der Nuklearmedizin 192, 422–430 (2020). https://doi.org/10.1055/a-1030-4631
J.Y. Kim, S.M. Hong, Recent updates on neuroendocrine tumors from the gastrointestinal and pancreatobiliary tracts. Arch. Pathol. Lab. Med. 140, 437–448 (2016). https://doi.org/10.5858/arpa.2015-0314-RA
A. Dasari, C. Shen, D. Halperin, B. Zhao, S. Zhou, Y. Xu, T. Shih, J.C. Yao, Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 3, 1335–1342 (2017). https://doi.org/10.1001/jamaoncol.2017.0589
E. Leoncini, P. Boffetta, M. Shafir, K. Aleksovska, S. Boccia, G. Rindi, Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine 58, 368–379 (2017). https://doi.org/10.1007/s12020-017-1273-x
G. Klöppel, Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr. Relat. Cancer 18(Suppl 1), S1–16 (2011). https://doi.org/10.1530/erc-11-0013
C. Fottner, M. Ferrata, M.M. Weber, Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): when to consider, how to diagnose? Rev. Endocr. Metab. Disord. 18, 393–410 (2017). https://doi.org/10.1007/s11154-017-9438-8
E. Lewkowicz, M. Trofimiuk-Müldner, K. Wysocka, D. Pach, A. Kiełtyka, A. Stefańska, A. Sowa-Staszczak, R. Tomaszewska, A. Hubalewska-Dydejczyk, Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center. Polskie Archiwum Med. Wewnetrznej 125, 337–346 (2015). https://doi.org/10.20452/pamw.2832
A.M. Bellizzi, Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you? Hum. Pathol. 96, 8–33 (2020). https://doi.org/10.1016/j.humpath.2019.12.002
Y. Goto, M.G. De Silva, A. Toscani, B.S. Prabhakar, A.L. Notkins, M.S. Lan, A novel human insulinoma-associated cDNA, IA-1, encodes a protein with “zinc-finger” DNA-binding motifs. J. Biol. Chem. 267, 15252–15257 (1992)
J. Xie, T. Cai, H. Zhang, M.S. Lan, A.L. Notkins, The zinc-finger transcription factor INSM1 is expressed during embryo development and interacts with the Cbl-associated protein. Genomics 80, 54–61 (2002). https://doi.org/10.1006/geno.2002.6800
R. Sakakibara, M. Kobayashi, N. Takahashi, K. Inamura, H. Ninomiya, R. Wakejima, S. Kitazono, N. Yanagitani, A. Horiike, J. Ichinose, Y. Matsuura, M. Nakao, M. Mun, M. Nishio, S. Okumura, N. Motoi, T. Ito, Y. Miyazaki, N. Inase, Y. Ishikawa, Insulinoma-associated Protein 1 (INSM1) Is a Better Marker for the Diagnosis and Prognosis Estimation of Small Cell Lung Carcinoma Than Neuroendocrine Phenotype Markers Such as Chromogranin A, Synaptophysin, and CD56. Am. J. Surgical Pathol. 44, 757–764 (2020). https://doi.org/10.1097/pas.0000000000001444
C. Leblebici, B. Yeni, T.C. Savli, Ö. Aydın, P. Güneş, L. Cinel, B. Şimşek, P. Yıldız, D. Tuncel, S. Kayahan, A new immunohistochemical marker, insulinoma-associated protein 1 (INSM1), for Merkel cell carcinoma: Evaluation of 24 cases. Ann. Diagnostic Pathol. 40, 53–58 (2019). https://doi.org/10.1016/j.anndiagpath.2019.04.002
Z. Maleki, M. Abram, M. Dell’Aquila, I. Kilic, R. Lu, T. Musarra, G. Barkan, E. Rajakorpi, E.D. Rossi, I. Kholová, Insulinoma-associated protein 1 (INSM-1) expression in medullary thyroid carcinoma FNA: a multi-institutional study. J. Am. Soc. Cytopathol. 9, 185–190 (2020). https://doi.org/10.1016/j.jasc.2020.01.005
B. Mahalakshmi, R. Baskaran, M. Shanmugavadivu, N.T. Nguyen, B.K. Velmurugan, Insulinoma-associated protein 1 (INSM1): a potential biomarker and therapeutic target for neuroendocrine tumors. Cell. Oncol. 43, 367–376 (2020). https://doi.org/10.1007/s13402-020-00505-9
D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6, e1000097 (2009). https://doi.org/10.1371/journal.pmed.1000097
P.F. Whiting, A.W. Rutjes, M.E. Westwood, S. Mallett, J.J. Deeks, J.B. Reitsma, M.M. Leeflang, J.A. Sterne, P.M. Bossuyt, QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 155, 529–536 (2011). https://doi.org/10.7326/0003-4819-155-8-201110180-00009
M. Wang, Y. Yang, J. Xu, W. Bai, X. Ren, H. Wu, CircRNAs as biomarkers of cancer: a meta-analysis. BMC Cancer 18, 303 (2018). https://doi.org/10.1186/s12885-018-4213-0
X.B. Liu, Z.Y. Gao, Q.H. Zhang, S. Jin, B. Gao, G.L. Yang, S.B. Li, Serum pepsinogen assay is not recommended for the diagnosis of esophageal squamous cell carcinoma: a systematic review and meta-analysis. Cancer Manag. Res. 11, 5643–5654 (2019). https://doi.org/10.2147/cmar.S196760
D. Kim, K. Viswanathan, A. Goyal, R. Rao, Insulinoma-associated protein 1 (INSM1) is a robust marker for identifying and grading pancreatic neuroendocrine tumors. Cancer Cytopathol. 128, 269–277 (2020). https://doi.org/10.1002/cncy.22242
Y. Takase, Y. Naito, Y. Okabe, Y. Ishida, T. Yamaguchi, H. Abe, K. Murata, T. Ito, M. Tanigawa, A. Kawahara, H. Yano, J. Akiba, Insulinoma-associated protein 1 expression in pancreatic neuroendocrine tumours in endoscopic ultrasound-guided fine-needle aspiration cytology: an analysis of 14 patients. Cytopathology 30, 194–200 (2019). https://doi.org/10.1111/cyt.12640
I. González, H.C. Lu, J. Sninsky, C. Yang, K. Bishnupuri, B. Dieckgraefe, D. Cao, D. Chatterjee, Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts. Histopathology 75, 568–577 (2019). https://doi.org/10.1111/his.13899
J. Wang, B. Wang, S. Gou, L. Yang, Q. Qi, W. Huang, Diagnostic value of INSM1 in gastroenteropancreatic neuroendocrine neoplasms. Chin. J. Clin. Exp. Pathol. 35, 407–411 (2019)
E.F. Rodriguez, J.J. Fite, S. Chowsilpa, Z. Maleki, Insulinoma-associated protein 1 immunostaining on cytology specimens: an institutional experience. Hum. Pathol. 85, 128–135 (2019). https://doi.org/10.1016/j.humpath.2018.10.035
K. Fujino, K. Yasufuku, S. Kudoh, Y. Motooka, Y. Sato, J. Wakimoto, I. Kubota, M. Suzuki, T. Ito, INSM1 is the best marker for the diagnosis of neuroendocrine tumors: comparison with CGA, SYP and CD56. Int J. Clin. Exp. Pathol. 10, 5393–5405 (2017)
M. Tanigawa, M. Nakayama, T. Taira, S. Hattori, Y. Mihara, R. Kondo, H. Kusano, K. Nakamura, Y. Abe, Y. Ishida, Y. Okabe, T. Hisaka, K. Okuda, K. Fujino, T. Ito, A. Kawahara, Y. Naito, R. Yamaguchi, J. Akiba, Y. Akagi, H. Yano, Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor. Med. Mol. Morphol. 51, 32–40 (2018). https://doi.org/10.1007/s00795-017-0167-6
J.N. Rosenbaum, Z. Guo, R.M. Baus, H. Werner, W.M. Rehrauer, R.V. Lloyd, INSM1: a novel immunohistochemical and molecular marker for neuroendocrine and neuroepithelial neoplasms. Am. J. Clin. Pathol. 144, 579–591 (2015). https://doi.org/10.1309/ajcpgzwxxbsnl4vd
K.E. McHugh, S. Mukhopadhyay, E.E. Doxtader, C. Lanigan, D.S. Allende, INSM1 is a highly specific marker of neuroendocrine differentiation in primary neoplasms of the gastrointestinal tract, appendix, and pancreas. Am. J. Clin. Pathol. 153, 811–820 (2020). https://doi.org/10.1093/ajcp/aqaa014
I. Nagtegaal, R. Odze, D. Klimstra, V. Paradis, M. Rugge, P. Schirmacher, M. Washington, F. Carneiro, I. Cree, The 2019 WHO classification of tumours of the digestive system. Histopathology 76 (2019). https://doi.org/10.1111/his.13975
A.M. Bellizzi, Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you? Hum. Pathol. 96, 8–33 (2020). https://doi.org/10.1016/j.humpath.2019.12.002
J.Y. Kim, S.M. Hong, J.Y. Ro, Recent updates on grading and classification of neuroendocrine tumors. Ann. Diagnostic Pathol. 29, 11–16 (2017). https://doi.org/10.1016/j.anndiagpath.2017.04.005
F.T. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise, WHO Classification of Tumours of the Digestive System 4th Edition, IARC, Lyon, 417p (2010).
Y. Ohara, T. Oda, S. Hashimoto, Y. Akashi, R. Miyamoto, T. Enomoto, K. Satomi, Y. Morishita, N. Ohkohchi, Pancreatic neuroendocrine tumor and solid-pseudopapillary neoplasm: Key immunohistochemical profiles for differential diagnosis. World J. Gastroenterol. 22, 8596–8604 (2016). https://doi.org/10.3748/wjg.v22.i38.8596
A.D. Herrera-Martínez, L.J. Hofland, M.A. Gálvez Moreno, J.P. Castaño, W.W. de Herder, R.A. Feelders, Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. Endocr. Relat. cancer 26, R157–r179 (2019). https://doi.org/10.1530/erc-18-035
A.P. Aldera, D. Govender, M.L. Locketz, S. Mukhopadhyay, K. McHugh, D. Allende, Combined use of INSM1 and synaptophysin is the most sensitive and specific panel to detect neuroendocrine neoplasms in the digestive tract. Am. J. Clin. Pathol. 154, 870–871 (2020). https://doi.org/10.1093/ajcp/aqaa164
Author information
Authors and Affiliations
Contributions
Q.Z., R.C., and J.H. put forward the original idea of this study and conducted a comprehensive search of the databases. Q.Z. and J.H. were responsible for study selection and data extraction. Q.Z., J.H., and Y.H. synthesized and analyzed the data and drafted the manuscript. J.S. reviewed the study and provided suggestions. All authors carefully examined this manuscript and agreed with the ideas of the research.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Ethical approval
All analyses were based on previous published studies and the original data are anonymous, thus no ethical approval and patient consent are required.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zhang, Q., Huang, J., He, Y. et al. Insulinoma-associated protein 1(INSM1) is a superior marker for the diagnosis of gastroenteropancreatic neuroendoerine neoplasms: a meta-analysis. Endocrine 74, 61–71 (2021). https://doi.org/10.1007/s12020-021-02754-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-021-02754-6